<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="phenyl group by a diene backbone (Table 1, #1). The" exact="nitro" post="group in the aryl moiety bears high risk for"/>
 <result pre="negative control compounds (#4 or #18).The HIV reverse transcriptase inhibitor" exact="Efavirenz" post="(EFV), the integrase inhibitor Dolutegravir (DTG) and the HIV"/>
 <result pre="reference compounds that prevent HIV integration, the reverse transcriptase inhibitor" exact="Efavirenz" post="(EFV), and the integrase inhibitor Dolutegravir (DTG). Treatment with"/>
 <result pre="we evaluated the combinatorial activities of the reverse transcriptase inhibitors" exact="Efavirenz" post="(EFV; NNRTI) and Emtricitabine (FTC; NRTI), which were previously"/>
 <result pre="activities of the reverse transcriptase inhibitors Efavirenz (EFV; NNRTI) and" exact="Emtricitabine" post="(FTC; NRTI), which were previously reported to synergistically inhibit"/>
 <result pre="(no shading)21,23. The following clinical drugs were used: RT inhibitors" exact="Emtricitabine" post="(FTC; panels a,f), Lamivudine (3TC, panel b), Efavirenz (EFV;"/>
 <result pre="clinical drugs were used: RT inhibitors Emtricitabine (FTC; panels a,f)," exact="Lamivudine" post="(3TC, panel b), Efavirenz (EFV; panels c,f); integrase inhibitor"/>
 <result pre="RT inhibitors Emtricitabine (FTC; panels a,f), Lamivudine (3TC, panel b)," exact="Efavirenz" post="(EFV; panels c,f); integrase inhibitor Dolutegravir (DTG; panel d);"/>
 <result pre="panels c,f); integrase inhibitor Dolutegravir (DTG; panel d); protease inhibitor" exact="Saquinavir" post="(SQV; panel e). Depicted are the means of at"/>
 <result pre="at the aryl moiety designed to replace the potentially toxic" exact="nitro" post="group with more favourable substituents like fluorine. Selective introduction"/>
 <result pre="Reference HIV-1 inhibitors Enfuvirtide (T-20; SML0934) was purchased from Sigma-Aldrich," exact="Emtricitabine" post="(FTC; ab145045) from abcam, Abacavir (ABC; Cay14746-10) from Biomol,"/>
 <result pre="SML0934) was purchased from Sigma-Aldrich, Emtricitabine (FTC; ab145045) from abcam," exact="Abacavir" post="(ABC; Cay14746-10) from Biomol, Lamivudine (3TC; T0682) and Dolutegravir"/>
 <result pre="Emtricitabine (FTC; ab145045) from abcam, Abacavir (ABC; Cay14746-10) from Biomol," exact="Lamivudine" post="(3TC; T0682) and Dolutegravir (DTG; T6198) from TargetMol, Efavirenz"/>
 <result pre="Biomol, Lamivudine (3TC; T0682) and Dolutegravir (DTG; T6198) from TargetMol," exact="Efavirenz" post="(EFV; 14412) and Saquinavir (SQV; 9001893) from Cayman. Cell"/>
 <result pre="and Dolutegravir (DTG; T6198) from TargetMol, Efavirenz (EFV; 14412) and" exact="Saquinavir" post="(SQV; 9001893) from Cayman. Cell viability and toxicity assays"/>
 <result pre="transfer inhibitor dolutegravir (S/GSK1349572)Mol. Pharmacol.20118056557210.1124/mol.111.07318921719464 12.HirataYNakataHYamadaKOkuharaKNaitoTThe structure of Aureothin, a" exact="nitro" post="compound obtained from Streptomyces thioluteusTetrahedron19611425227410.1016/S0040-4020(01)92175-1 13.HallLHMaynardELKierLBStructure-activity relationship studies on"/>
 <result pre="enzyme inhibitorsAdv. Enzyme Regul.198422275510.1016/0065-2571(84)90007-46382953 23.FengJYet al.The triple combination of tenofovir," exact="emtricitabine" post="and efavirenz shows synergistic anti-HIV-1 activity in vitro: a"/>
 <result pre="Enzyme Regul.198422275510.1016/0065-2571(84)90007-46382953 23.FengJYet al.The triple combination of tenofovir, emtricitabine and" exact="efavirenz" post="shows synergistic anti-HIV-1 activity in vitro: a mechanism of"/>
</results>
